Survey on the SARS-CoV-2 additional vaccinatio

Not Applicable

• Conditions: Severe acute respiratory syndrome coronavirus 2; SARS-CoV-2 infection; D000086402

• Registration Number: JPRN-jRCT1061210049
• Lead Sponsor: akano Takashi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

School staff who are participating in jRCT1061200057 research and receive the additional SARS-CoV-2 vaccination in December 2021

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Transition of SARS-CoV-2 serum antibody titer after the SARS-CoV-2 additional vaccination

Secondary Outcome Measures

Name	Time	Method
Transition ofHealth condition after the SARS-CoV-2 additional vaccination<br>Backgroud factor that is contribute transition of SARS-CoV-2 serum antibody titer